NewLimit, founded by the Coinbase CEO, has completed a $130 million Series B funding round with Kleiner Perkins as the lead investor.

BlockBeats News, May 6th, Anti-aging company NewLimit, founded by Coinbase CEO Brian Armstrong, announced the completion of a $130 million Series B funding round. This round of funding was led by Kleiner Perkins, with participation from Nat Friedman, Daniel Gross, and Khosla Ventures, among others.

NewLimit aims to extend people's healthy lifespan through genetic programming of cells. Founded four years ago by Brian Armstrong, former GV partner Blake Bryers, and stem cell professor Jacob Kimmel, the company claims to have made significant progress in developing a therapeutic approach to rejuvenate aging cells.

The company has identified three prototype drugs that can reprogram liver cells. Bryers stated that laboratory experiments at NewLimit have shown that this regeneration therapy can restore the cells' ability to process fat and alcohol. The company measures its progress by comparing how cells from young and old individuals respond to these substances. Liver cells processed through NewLeaf epigenetic reprogramming behave more like young cells.

Despite promising early results, NewLimit is still several years away from starting human trials.